Member Info for mulledwine

http://www.investegate.co.uk/Article.aspx?id=201204050700218764A

Panmure Gordon maintained its "buy" stance for YouGov (YOU) with a 85p target price. The market research company delivered a strong first half performance for the 2012 financial year ending in July, with revenue growth of 12% and the broker noted the planned launch of two new products which could drive growth in 2013, the Executive Dashboard and Social Media Analysis Tool (SoMA). Panmure believes that the release of the SoMA is likely to coincide with the IPO of Facebook, which should increase the awareness of the product. The broker also pointed out that YouGov will introduce a maiden dividend at the end of the financial year

N+1 Brewin retained its "add" rating for Hilton Food (HFG) with a target price of 320p. The meat packaging company achieved revenues of 981.3 million pounds for the year ended 1st January 2012, beating the broker's forecast of 946.6 million pounds. Brewin noted a strong performance in western Europe, which accounted for 90% of EBIT, while eastern Europe trading suffered from inflation restricting volume growth. The broker pointed to the group's high cash generative ability, with net debt reduced to 18.7 million pounds, compared to the broker's expected 21.8 million pounds

Singer Capital reiterated its "buy" recommendation for Ashmore (ASHM) with a 445p target price. The broker expects the investment management fund to report assets under management to rise by 4.5 billion dollars (2.8 billion pounds) to 64.9 billion dollars (40.9 billion pounds) over the three months ended 31st March, benefiting from a strong investment performance over the period. Singer noted that the shares have underperformed the market since a lackluster interim report in February, but expects the third quarter update to have a positive impact on the price.

Wolfhart Hauser, Chief Executive Officer of Intertek, commented: "We are pleased to welcome the company to the Group. ATI's solutions are highly complementary to our wider Industry Services portfolio and will deepen our support to customers in maintaining the quality of their assets."

Intertek acquires Automation Technology Inc (ATI) Intertek Group plc (Intertek), the leading international provider of quality services to a wide range of industries, announces that it has acquired ATI, a provider of asset integrity support services in the US power sector. The company was purchased from its management shareholders for a total consideration of USD 16 million (GBP 10 million). ATI's asset management software solutions are used to record and collate testing and inspection data to support the maintenance of power generation infrastructure. It helps companies to track infrastructure integrity and to develop effective plans to reduce failure risk and optimise maintenance work during scheduled outage periods. Power and energy companies are investing more in solutions such as those of ATI which help to regulate and manage their maintenance programmes as they continue to increase investment in existing and new infrastructure to meet growth in energy demand. ATI will complement Intertek's existing quality and integrity management services for owners and operators of power, oil, gas, petrochemical, renewable energy and other infrastructure. The company is based in California, USA and will form part of Intertek's Industry & Assurance division.

http://www.investegate.co.uk/Article.aspx?id=201204050700208757A

farmhouse - you may not be far away - its certainly pointing in that direction and getting ever closer

Morgan Stanley downgrades Carphone Warehouse from equal weight to underweight, target price cut from 175p to 125p

Dr. Ian Pike, Chief Operating Officer of Proteome Sciences said "We are pleased to be partnering our advanced stroke biomarkers with Randox who are rapidly developing a strong presence in the CNS area. Their track record of new product introductions has been impressive and we see their testing platforms as an ideal setting for rapid stroke diagnosis." Dr. Peter FitzGerald, Managing Director at Randox commented "the addition of the Proteome Sciences stroke biomarkers will add significantly to the range of diagnostic products we offer in the cardiovascular disease field. Our ability to deliver these novel biomarkers to healthcare providers using our Biochip Array systems will enable stratification of patients for appropriate treatment and contribute to a reduction in healthcare costs. The stroke biomarkers will be offered to hospital laboratories through our global distribution network in 130 countries Christopher Pearce, Chief Executive of Proteome Sciences said "The stroke biomarkers licensed to Randox have the ability to transform the way stroke is managed and ensure that considerably more patients receive treatment early. This will reduce the levels of disability, lower the cost of care and improve patient outcomes. We are delighted that the importance of our proprietary biomarkers is being properly recognised in diagnostics and drug development. Whilst licensing to companies like Randox remains a key component of our business, we also provide direct testing services through our ISO 9001:2008 certified facility and rapidly increased the number of biomarkers where we had assay coverage to around 50 by the end of 2011 and this number will double in 2012 with revenue reflected through PS Biomarker Services™."

Stroke Biomarker License to Randox 5th April 2012, London. Proteome Sciences plc, a global leader in protein biomarkers has today granted a non-exclusive license to Randox Laboratories ("Randox") of Crumlin, UK for its portfolio of stroke biomarkers. Proteome Sciences has established an extensive portfolio of patented plasma biomarkers of stroke and other brain damage-related disorders discovered in partnership with the Biomedical Proteomics Research Group at the University of Geneva ("BPRG"). These markers are rapidly elevated in blood of patients undergoing both haemorrhagic and ischaemic strokes and offer the potential to identify those patients that would most benefit from thrombolytic treatment within the first 3 hours after onset of symptoms. The research with BPRG has shown that a panel of 5 blood proteins is able to accurately rule out 90% [9 out of 10] of patients that have not had a stroke but who may currently be misdiagnosed in primary care and allows 90% [9 out of 10] of genuine strokes to be confirmed within minutes of the onset of symptoms. Together, these results have the potential to transform the management of acute stroke and ensure more patients receive thrombolytic therapy. These provide a highly effective way to minimise long-term disability in ischaemic stroke, reduce the cost of care and considerably improve the quality of life for stroke patients and their families. Under the terms of the Agreement Randox will develop products for early diagnosis of stroke and subsequent monitoring of treatment outcomes. Financial terms provide Proteome Sciences with seven digit (US dollar) license and development milestones together with double digit royalties on sales. The clinical discovery and validation of the stroke biomarkers was led by Prof Jean-Charles Sanchez, Director of the University of Geneva Biomedical Proteomics Research Group who commented " The discovery and validation of a panel of early stroke biomarkers in blood opens the way for rapid detection and selection of treatment that will have profound benefits for patients, their families and carers. We have recently studied the potential impact of using just one of these markers, GST-Pi, and found it could increase the number of treated stroke patients five-fold."

http://www.investegate.co.uk/Article.aspx?id=201204050700218769A

Next Buy 04-Apr-12 £124,067.33 C E Angelides 4,196 @ 2,956.80p Next Buy 04-Apr-12 £99,259.78 Andrew John Varley 3,357 @ 2,956.80p Next Buy 04-Apr-12 £99,259.78 David W Keens 3,357 @ 2,956.80p

Conclusion The current portfolio, while concentrated, has had a good 2011, with real revenue growth, a clear focus on profitability and a simplified and transparent investment structure. The prospects for further growth in the value of these investments during 2012 are favourable. The Company has exited from non-core investments and has sufficient cash on its balance sheet. The Company is now in a stronger place from which to move forward. We look forward to creating significant value and capital gains for the Company's investors.

Christopher Hill, Chairman of International Oil and Gas Technology Limited, said: "The past twelve months have seen your Company make considerable strides in restoring its own financial strength and in rebuilding value in its portfolio companies. The Board and the Investment Manager have worked together closely to create a platform from which the Company can grow again. I am confident that 2012 will see further significant progress." David Sefton, Partner at Linton Capital, Investment Manager of IOGT, said: "Following the restructuring of the portfolio in 2012, the Company has emerged in a strong position with three investee companies that show considerable opportunity for growth and capital gain for shareholders. The Company has taken the prudent step of retaining sufficient cash to enable it to fund that growth. The Investment Manager continues to see highly attractive investment opportunities in the oil and gas technology and services sector. We believe that a disciplined focus on growth investing in companies that deliver a differentiated service at the wellhead will prove to be a profitable investment strategy for IOGT."

Final Results International Oil and Gas Technology Limited (LSE:OGT), an authorised closed-ended investment company incorporated in Guernsey, today announces its final results for the year ended 31 December 2011. Highlights · Net Asset Value ("NAV") increased by 16% to US$10.30 (2010: US$8.88) · Financial performance of Strata has exceeded expectations · SR2020 experiencing increased market demand and growth opportunity · Crest has commenced revenue-generating operations in the Middle East with further operational opportunities now available · Successful disposals of interests in WellPoint Systems and LxData for a total cash consideration of US$24.1 million · Cash reserve primarily allocated to allow Strata, SR2020 and Crest to meet growth opportunities

http://www.investegate.co.uk/Article.aspx?id=201204050703138747A

March Production Report 5 April 2012 5 April 2012 - Exillon Energy plc ("Exillon Energy", the "Company" or the "Group") (EXI.LN), a London listed independent oil producer with assets in two oil-rich regions of Russia, Timan-Pechora ("Exillon TP") and West Siberia ("Exillon WS"), is pleased to announce unaudited production data for the month of March 2012 ("the Period"). · Average daily production[1] for the Group was 11,785 bbl/day during the period. · Average daily production for Exillon TP was 3,261 bbl/day, and for Exillon WS it was 8,525 bbl/day during the period. · Peak daily production[2] for the Group was 12,177 bbl/day during the period. The Company expects to make the April production announcement by 15 May 2012.

http://www.investegate.co.uk/Article.aspx?id=201204050700238961A

Nearly back to low point just after admission - its been one way since turn of year and thats down - will she turn - possibly not yet